{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:35:52Z","timestamp":1753889752302,"version":"3.41.2"},"reference-count":61,"publisher":"Bentham Science Publishers Ltd.","issue":"9","license":[{"start":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T00:00:00Z","timestamp":1690934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background and Aims:<\/jats:title>\n<jats:p>Hypoglycemia and insulin-related adverse events are crucial\nbarriers to effective diabetes management, particularly in the elderly, people with renal impairment,\npeople with diabetes fasting during Ramadan, or people with type 1 diabetes mellitus\n(T1DM). There is a scarcity of clinical and real-world evidence assessing the effectiveness and\nsafety of insulin glargine 300 U\/mL (Gla-300) in these special populations. To understand the entirety\nof evidence, this mini-review elaborates on the use of Gla-300 in diabetes management\namong special populations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Clinical and real-world evidence related to the use of Gla-300 among special populations\nwith diabetes were retrieved using PUBMED and Google Scholar.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Gla-300 has shown improved glycemic control with stable insulin action and low risk of\nhypoglycemia in diverse groups with diabetes. It also appears to have an acceptable safety profile\nduring Ramadan fasting. However, adequate monitoring and adjustment of insulin dose on an individual\nbasis should be considered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Gla-300 is a second-generation basal insulin with proven benefits of reduced risk of\nhypoglycemia and improved glycemic control in special populations of people with diabetes.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573399819666230109113205","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T05:45:03Z","timestamp":1673329503000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of Second-Generation Basal Insulin Gla-300 in Special Populations: A\nNarrative Mini-Review"],"prefix":"10.2174","volume":"19","author":[{"given":"Sujoy","family":"Ghosh","sequence":"first","affiliation":[{"name":"Department of Endocrinology, IPGME &amp; R, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Bharti Hospital,\nKarnal, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganapathi","family":"Bantwal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. John\u2019s Medical College &amp; Hospital, Bengaluru, Karnataka,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh Kumar","family":"Sahay","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"Zoungas S.","year":"2010","unstructured":"Zoungas S.; Patel A.; Chalmers J.; Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010,363(15),1410-1418","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4093\/dmj.2016.40.6.423","volume":"40","author":"Yun J.S.","year":"2016","unstructured":"Yun J.S.; Ko S.H.; Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J 2016,40(6),423-432","journal-title":"Diabetes Metab J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"Wysham C.","year":"2017","unstructured":"Wysham C.; Bhargava A.; Chaykin L.; Effect of insulin degludec vs. insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 2017,318(1),45-56","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1001\/jamainternmed.2013.12956","volume":"174","author":"Huang E.S.","year":"2014","unstructured":"Huang E.S.; Laiteerapong N.; Liu J.Y.; John P.M.; Moffet H.H.; Karter A.J.; Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014,174(2),251-258","journal-title":"JAMA Intern Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1210\/jc.2009-2828","volume":"95","author":"Davis T.M.E.","year":"2010","unstructured":"Davis T.M.E.; Brown S.G.A.; Jacobs I.G.; Bulsara M.; Bruce D.G.; Davis W.A.; Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab 2010,95(5),2240-2247","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1464-5491.2007.02341.x","volume":"25","author":"Amiel S.A.","year":"2008","unstructured":"Amiel S.A.; Dixon T.; Mann R.; Jameson K.; Hypoglycaemia in type 2 diabetes. Diabet Med 2008,25(3),245-254","journal-title":"Diabet Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/dom.12416","volume":"17","author":"Becker R.H.A.","year":"2015","unstructured":"Becker R.H.A.; Nowotny I.; Teichert L.; Bergmann K.; Kapitza C.; Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml. Diabetes Obes Metab 2015,17(3),261-267","journal-title":"Diabetes Obes Metab"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/dc16-0684","volume":"40","author":"Bergenstal R.M.","year":"2017","unstructured":"Bergenstal R.M.; Bailey T.S.; Rodbard D.; Comparison of insulin glargine 300 units\/mL and 100 units\/mL in adults with type 1 diabetes: Continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care 2017,40(4),554-560","journal-title":"Diabetes Care"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","volume":"53","author":"Haahr H.","year":"2014","unstructured":"Haahr H.; Heise T.; A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014,53(9),787-800","journal-title":"Clin Pharmacokinet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1463-1326.2012.01638.x","volume":"14","author":"Heise T.","year":"2012","unstructured":"Heise T.; Nosek L.; B&#xF8;ttcher S.G.; Hastrup H.; Haahr H.; Ultra-long-\nacting insulin degludec has a flat and stable glucose-lowering effect\nin type 2 diabetes. Diabetes Obes Metab 2012,14(10),944-950","journal-title":"Diabetes Obes Metab"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.mayocp.2014.07.013","volume":"89","author":"Alsahli M.","year":"2014","unstructured":"Alsahli M.; Gerich J.E.; Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc 2014,89(11),1564-1571","journal-title":"Mayo Clin Proc"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.2215\/CJN.00800209","volume":"4","author":"Moen M.F.","year":"2009","unstructured":"Moen M.F.; Zhan M.; Hsu V.D.; Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009,4(6),1121-1127","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm4050948","volume":"4","author":"Alsahli M.","year":"2015","unstructured":"Alsahli M.; Gerich J.; Hypoglycemia in patients with diabetes and renal disease. J Clin Med 2015,4(5),948-964","journal-title":"J Clin Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"Inzucchi S.E.","year":"2015","unstructured":"Inzucchi S.E.; Bergenstal R.M.; Buse J.B.; Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015,38(1),140-149","journal-title":"Diabetes Care"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","year":"2012","unstructured":"KDOQI Clinical practice guideline for diabetes and CKD: 2012 Update. Am J Kidney Dis 2012,60(5),850-886","journal-title":"Am J Kidney Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2337\/dc15-0858","volume":"39","author":"Pathak R.D.","year":"2016","unstructured":"Pathak R.D.; Schroeder E.B.; Seaquist E.R.; Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. Integrated Health Care Delivery Systems:2005-2011. Diabetes Care 2016,39(3),363-370","journal-title":"Diabetes Care"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1111\/dom.13470","volume":"20","author":"Javier Escalada F.","year":"2018","unstructured":"Javier Escalada F.; Halimi S.; Senior P.A.; Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U\/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. Diabetes Obes Metab 2018,20(12),2860-2868","journal-title":"Diabetes Obes Metab"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/dom.14043","volume":"22","author":"Haluz&#xED;k M.","year":"2020","unstructured":"Haluz&#xED;k M.; Cheng A.; M&#xFC;ller-Wieland D.; Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. Diabetes Obes Metab 2020,22(8),1369-1377","journal-title":"Diabetes Obes Metab"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s13300-021-01031-z","volume":"12","author":"Mauricio D.","year":"2021","unstructured":"Mauricio D.; Gourdy P.; Bonadonna R.C.; Glycaemic control with insulin glargine 300 U\/ml in individuals with type 2 diabetes and chronic kidney disease: A REALI European Pooled Data Analysis. Diabetes Ther 2021,12(4),1159-1174","journal-title":"Diabetes Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/dom.13345","volume":"20","author":"Sullivan S.D.","year":"2018","unstructured":"Sullivan S.D.; Bailey T.S.; Roussel R.; Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units\/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab 2018,20(9),2148-2158","journal-title":"Diabetes Obes Metab"},{"author":"Sullivan S.D.","key":"ref=21","unstructured":"Sullivan S.D.; Freemantle N.; Menon A.A.;  High Hypoglycemia  Risk Patients with Type 2 Diabetes on First Generation Basal Insulins (BIs) in the us Have a Lower Risk of Hypoglycemia after 1 year Following Switch to Insulin Glargine 300 U\/mL versus First  Generation BIs (DELIVER \u2013 High Risk). Poster 133 LB, American Diabetes Association (ADA) 79th Scientific Sessions, San Francisco, CA, US. June 7 11, 2019. Available from:  (Accessed on: 10 Oct 2021)."},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s13300-019-0568-8","volume":"10","author":"Pettus J.","year":"2019","unstructured":"Pettus J.; Roussel R.; Liz Zhou F.; Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U\/ml versus first- and second-generation basal insulin analogs: the real-world lightning study. Diabetes Ther 2019,10(2),617-633","journal-title":"Diabetes Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1038-P","DOI":"10.2337\/db20-1038-P","volume":"69","author":"Meneghini L","year":"2020","unstructured":"Meneghini L; Cheng A; Evenou P; 1038-P: Insulin glargine 300 U\/mL (gla-300) vs. first-generation standard-of-care basal insulin analogs (SOC-BI) in insulin-na&#xEF;ve patients with type 2 diabetes (T2D): impact of renal function on the outcomes of the randomized pragmatic real-life achieve control study. Diabetes 2020,69(Supplement 1),1038-P"},{"key":"ref=24","unstructured":"ClinicalTrials.gov Identifier: NCT03703869: Twelve -month study observing how insulin-na&#xEF;ve patients with type 2 diabetes mellitus manage diabetes using toujeo&#xAE; after oral antidiabetic drug failure, the side effect of toujeo&#xAE;, and the cost. (ATOS). Available from:  (Accessed on: 22 October 2021)."},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"743-P","DOI":"10.2337\/db21-743-P","volume":"70","author":"Tirosh A","year":"2021","unstructured":"Tirosh A; Khan N; Vargas-Uricoechea H; 743-P: Real-world effectiveness and safety of insulin glargine 300 U\/mL (gla-300) in insulin-na&#xEF;ve people with type 2 diabetes (T2DM) and renal impairment (RI): a subgroup analysis of the ATOS study. Diabetes 2021,70(S1),743-P"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13300-019-0654-y","volume":"10","author":"Kawaguchi Y.","year":"2019","unstructured":"Kawaguchi Y.; Sawa J.; Hamai C.; Kumeda Y.; Differential effect of hypoalbuminemia on hypoglycemia on type 2 diabetes patients treated with insulin glargine 300 U\/mL and insulin degludec. Diabetes Ther 2019,10(4),1535-1541","journal-title":"Diabetes Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.14336\/AD.2014.0330","volume":"6","author":"Abdelhafiz A.H.","year":"2015","unstructured":"Abdelhafiz A.H.; Rodr&#xED;guez-Ma&#xF1;as L.; Morley J.E.; Sinclair A.J.; Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis 2015,6(2),156-167","journal-title":"Aging Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.2337\/dc12-1801","volume":"35","author":"Kirkman M.S.","year":"2012","unstructured":"Kirkman M.S.; Briscoe V.J.; Clark N.; Diabetes in older adults. Diabetes Care 2012,35(12),2650-2664","journal-title":"Diabetes Care"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1080\/03007995.2016.1189893","volume":"32","author":"Escalada J.","year":"2016","unstructured":"Escalada J.; Liao L.; Pan C.; Wang H.; Bala M.; Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting. Curr Med Res Opin 2016,32(9),1557-1565","journal-title":"Curr Med Res Opin"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2337\/dc18-0168","volume":"41","author":"Ritzel R.","year":"2018","unstructured":"Ritzel R.; Harris S.B.; Baron H.; A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units\/ml versus 100 Units\/mL in older people with type 2 diabetes: results from the senior study. Diabetes Care 2018,41(8),1672-1680","journal-title":"Diabetes Care"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.002","volume":"46","author":"Yale J.F.","year":"2020","unstructured":"Yale J.F.; Aroda V.R.; Charbonnel B.; Glycaemic control and hypoglycaemia risk with insulin glargine 300 U\/mL versus glargine 100 U\/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab 2020,46(2),110-118","journal-title":"Diabetes Metab"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4158\/EP171922.OR","volume":"24","author":"Munshi M.N.","year":"2018","unstructured":"Munshi M.N.; Gill J.; Chao J.; Nikonova E.; Patel M.; Insulin glargine 300 u\/ml is associated with less weight gain while maintaining glycemic control and low risk of hypoglycemia compared with insulin glargine 100 u\/ml in an aging population with type 2 diabetes. Endocr Pract 2018,24(2),143-149","journal-title":"Endocr Pract"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2337\/db19-131-LB","volume":"68","author":"Charbonnel B.","year":"2019","unstructured":"Charbonnel B.; Aroda V.R.; Westerbacka J.; #131-LB. Differences in HbA1c reduction between insulin glargine 300 U\/mL (Gla-300) and insulin degludec 100 U\/mL (IDeg-100) in adults \u226570 years of age with T2DM in the bright trial. ADA 2019. Diabetes 2019,68(Supplement 1),131-LB","journal-title":"Diabetes"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/dom.14372","volume":"23","author":"Bolli G.B.","year":"2021","unstructured":"Bolli G.B.; Cheng A.; Charbonnel B.; Glycaemic control and hypoglycaemia risk with insulin glargine 300 U\/mL and insulin degludec 100 U\/mL in older participants in the BRIGHT trial. Diabetes Obes Metab 2021,23(7),1588-1593","journal-title":"Diabetes Obes Metab"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1111\/dom.13818","volume":"21","author":"Bailey T.S.","year":"2019","unstructured":"Bailey T.S.; Wu J.; Zhou F.L.; Switching to insulin glargine 300 units\/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes Obes Metab 2019,21(11),2384-2393","journal-title":"Diabetes Obes Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s13300-021-01030-0","volume":"12","author":"Bonadonna R.C.","year":"2021","unstructured":"Bonadonna R.C.; Mauricio D.; M&#xFC;ller-Wieland D.; Impact of age on the effectiveness and safety of insulin glargine 300 U\/ml: results from the reali European pooled data analysis. Diabetes Ther 2021,12(4),1073-1097","journal-title":"Diabetes Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"108647","DOI":"10.1016\/j.diabres.2020.108647","volume":"172","author":"Hirose T.","year":"2021","unstructured":"Hirose T.; Odawara M.; Matsuhisa M.; Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U\/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study). Diabetes Res Clin Pract 2021,172,108647","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db21-194-OR","volume":"70","author":"Galstyan G.R.","year":"2021","unstructured":"Galstyan G.R.; Tirosh A.; Vargas-Uricoechea H.; 194-OR: Real-world effectiveness and safety of insulin glargine 300 U\/mL (Gla-300) in older adults (\u226570 Years) with type 2 diabetes (T2DM): A subgroup analysis of the ATOS study. Diabetes 2021,70(Supplement 1),194-OR","journal-title":"Diabetes"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","volume":"44","author":"Bailey T.S.","year":"2018","unstructured":"Bailey T.S.; Pettus J.; Roussel R.; Morning administration of 0.4 U\/kg\/day insulin glargine 300 U\/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U\/mL in type 1 diabetes. Diabetes Metab 2018,44(1),15-21","journal-title":"Diabetes Metab"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2337\/dc20-1033","volume":"44","author":"Lucidi P.","year":"2021","unstructured":"Lucidi P.; Candeloro P.; Cioli P.; Pharmacokinetic and pharmacodynamic\nhead-to-head comparison of clinical, equivalent doses\nof insulin glargine 300 units &#xB7; mL and insulin degludec 100\nunits &#xB7; mL in type 1 diabetes. Diabetes Care 2021,44(1),125-132","journal-title":"Diabetes Care"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2337\/dc18-0706","volume":"42","author":"Porcellati F.","year":"2019","unstructured":"Porcellati F.; Lucidi P.; Candeloro P.; Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes. Diabetes Care 2019,42(1),85-92","journal-title":"Diabetes Care"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/1932296817731422","volume":"12","author":"Heise T.","year":"2018","unstructured":"Heise T.; Kaplan K.; Haahr H.L.; Day-to-day and within-day variability in glucose-lowering effect between insulin degludec and insulin glargine (100 U\/mL and 300 U\/mL): a comparison across studies. J Diabetes Sci Technol 2018,12(2),356-363","journal-title":"J Diabetes Sci Technol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc15-0249","volume":"38","author":"Home P.D.","year":"2015","unstructured":"Home P.D.; Bergenstal R.M.; Bolli G.B.; New insulin glargine 300 units\/ml versus glargine 100 units\/ml in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015,38(12),2217-2225","journal-title":"Diabetes Care"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1111\/dom.14109","volume":"22","author":"Danne T.","year":"2020","unstructured":"Danne T.; Matsuhisa M.; Sussebach C.; Lower risk of severe\nhypoglycaemia with insulin glargine 300 U\/ mL versus glargine\n100 U\/ mL in participants with type 1 diabetes: a meta-analysis of\n6-month phase 3 clinical trials. Diabetes Obes Metab 2020,22(10),1880-1885","journal-title":"Diabetes Obes Metab"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/dc19-1926","volume":"43","author":"Danne T.","year":"2020","unstructured":"Danne T.; Tamborlane W.V.; Malievsky O.A.; Efficacy and safety of insulin glargine 300 Units\/mL (gla-300) versus insulin glargine 100 Units\/mL (gla-100) in children and adolescents (6\u201317 years) with type 1 diabetes: results of the edition junior randomized controlled trial. Diabetes Care 2020,43(7),1512-1519","journal-title":"Diabetes Care"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/dom.12619","volume":"18","author":"Matsuhisa M.","year":"2016","unstructured":"Matsuhisa M.; Koyama M.; Cheng X.; New insulin glargine 300 U\/ml versus glargine 100 U\/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab 2016,18(4),375-383","journal-title":"Diabetes Obes Metab"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13300-019-00749-1","volume":"11","author":"Mathieu C.","year":"2020","unstructured":"Mathieu C.; Weisnagel S.J.; Stella P.; Bruhwyler J.; Alexandre K.; Impact of switching from twice-daily basal insulin to once-daily insulin glargine 300 U\/mL in people with type 1 diabetes on basal\u2013bolus insulin: phase 4 optimize study. Diabetes Ther 2020,11(2),495-507","journal-title":"Diabetes Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13098-019-0473-3","volume":"11","author":"Rea R.R.","year":"2019","unstructured":"Rea R.R.; Dib S.A.; de Paula M.A.; P146: Impact of switching from twice-daily (bid) basal insulin to once-daily (OD) insulin glargine 300 U\/ml (GLA-300) in patients with type 1 diabetes (T1D)-phase 4 TOP1 trial, Brazilian cohort. 22nd Brazilian Diabetes Society Congress. Diabetol Metab Syndr 2019,11(S1),146","journal-title":"Diabetol Metab Syndr"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1031-P","DOI":"10.2337\/db18-1031-P","volume":"67","author":"Fritsche A","year":"2018","unstructured":"Fritsche A; Pscherer S; Anderten H; Pegelow K; Seufert J; Pfohl M; Switching to insulin glargine 300 U\/mL (Gla-300) improves glycemic control after failure of basal-bolus therapy (BBT) with other basal insulins (BI) in patients (Pts) with type 1 diabetes (T1DM). Diabetes 2018,67(S1),1031-P"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.endien.2018.09.002","volume":"66","author":"Pujante A.P.","year":"2019","unstructured":"Pujante A.P.; Rodr&#xED;guez E.R.; Garc&#xED;a U.F.; Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life. Endocrinolog&#xED;a, Diabetes y Nutrici&#xF3;n 2019,66(4),210-216","journal-title":"Endocrinolog&#xED;a, Diabetes y Nutrici&#xF3;n"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1786-P","DOI":"10.2337\/db18-1786-P","volume":"67","author":"Quansah KA","year":"2018","unstructured":"Quansah KA; Sauriol L; Kukaswadia AA; Bremner S; Millson B; Persistence with insulin glargine 300 IU\/mL compared with other basal insulins-a canadian retrospective cohort study. Diabetes 2018,67(Suppl. 1),1786-P"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-019-00983-w","volume":"36","author":"van Mark G.","year":"2019","unstructured":"van Mark G.; Lanzinger S.; Sziegoleit S.; Characteristics of patients with type-1 or type-2 diabetes receiving insulin glargine u300: an analysis of 7268 patients based on the DPV and DIVE Registries. Adv Ther 2019,36(7),1628-1641","journal-title":"Adv Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/dme.13847","volume":"36","author":"Pang T.","year":"2019","unstructured":"Pang T.; Bain S.C.; Black R.N.A.; A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units\/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA). Diabet Med 2019,36(1),110-119","journal-title":"Diabet Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/17446651.2018.1469405","volume":"13","author":"Oriot P.","year":"2018","unstructured":"Oriot P.; J&#xE9;r&#xE9;mie W.; Buysschaert M.; Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U\/ml to glargine 300 U\/ml in real life. Expert Rev Endocrinol Metab 2018,13(3),167-171","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jcjd.2019.04.012","volume":"43","author":"Abitbol A.","year":"2019","unstructured":"Abitbol A.; Brown R.E.; Jiandani D.; Sauriol L.; Aronson R.; Real-world health outcomes of insulin glargine 300 U\/mL vs. insulin glargine 100 U\/mL in adults with type 1 and type 2 diabetes in the canadian LMC diabetes patient registry: The REALITY Study. Can J Diabetes 2019,43(7),504-509.e1","journal-title":"Can J Diabetes"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13300-020-00982-z","volume":"12","author":"Laviola L.","year":"2021","unstructured":"Laviola L.; Porcellati F.; Bruttomesso D.; Larosa M.; Rossi M.C.; Nicolucci A.; Comparative effectiveness of switching from first-generation basal insulin to glargine 300 U\/ml or degludec 100 U\/ml in type 1 diabetes: The restore-1 study. Diabetes Ther 2021,12(2),509-525","journal-title":"Diabetes Ther"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s13300-021-01153-4","volume":"12","author":"Conget I.","year":"2021","unstructured":"Conget I.; Mangas M.&#xC1;.; Morales C.; Effectiveness and safety of insulin glargine 300 U\/mL in comparison with insulin degludec 100 u\/ml evaluated with continuous glucose monitoring in adults with type 1 diabetes and suboptimal glycemic control in routine clinical practice: the onecare study. Diabetes Ther 2021,12(11),2993-3009","journal-title":"Diabetes Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.diabres.2016.10.002","volume":"122","author":"Matsuhisa M.","year":"2016","unstructured":"Matsuhisa M.; Koyama M.; Cheng X.; Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U\/mL compared with glargine 100 U\/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract 2016,122,133-140","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14656566.2020.1810665","volume":"22","author":"Matsuhisa M.","year":"2021","unstructured":"Matsuhisa M.; Odawara M.; Hirose T.; Real-world data on the use of insulin glargine 300 U\/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother 2021,22(2),249-256","journal-title":"Expert Opin Pharmacother"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dom.13048","volume":"20","author":"Home P.D.","year":"2018","unstructured":"Home P.D.; Bergenstal R.M.; Bolli G.B.; Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab 2018,20(1),121-128","journal-title":"Diabetes Obes Metab"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"108189","DOI":"10.1016\/j.diabres.2020.108189","volume":"166","author":"Hassanein M.","year":"2020","unstructured":"Hassanein M.; Buyukbese M.A.; Malek R.; Real-world safety and effectiveness of insulin glargine 300 U\/mL in participants with type 2 diabetes who fast during Ramadan: The observational ORION study. Diabetes Res Clin Pract 2020,166,108189","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666230109113205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/212447\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573399819666230109113205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:40:28Z","timestamp":1697460028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/212447\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573399819666230109113205","relation":{},"ISSN":["1573-3998"],"issn-type":[{"type":"print","value":"1573-3998"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e090123212447"}}